Open for inclusion

Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (MK1454-002)

Cancer type: Head and Neck cancer

Phase: II

Principal Investigator: Bratland Åse

Country: NO

Keywords: Norway, Oslo, Bergen, head and neck, MK1454, pembrolizumab, keytruda

Status: Open for inclusion

Link to